LY294002

Catalog No.S1105 Synonyms: SF 1101, NSC 697286

LY294002 Chemical Structure

Molecular Weight(MW): 307.34

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 70 Publications

13 Customer Reviews

  • Type I IFNs induce ISG expression in a serine phosphorylation-independent manner. Cells were treated with kinase inhibitors (SB203580, rottlerin, Ly294002, PD98059, and SP600125) before stimulation with IFN-a and IFN-b for 6 hours. Cell lysates were used in western blotting and probed for serine phosphorylation.The relative amounts of pSTAT1 S727 in (up-graph) were quantied and normalized to an untreated control (below-graph).

    Hepatology 2014 59(4), 1262-72. LY294002 purchased from Selleck.

    different signal-inhibitory profile by applying 120 nmol/L BGT226, 20 μmol/L LY294002, or 100 nmol/L rapamycin in FaDu cells.

    Clin Cancer Res 2011 17, 7116-7126. LY294002 purchased from Selleck.

  • Stimulation response of p37d-expressing cells. (c) Western blot of 5 min serum stimulated HEK-293 cells stably expressing p37d, p110d or control, with the presence of inhibitors as indicated at the top.

    Oncogene 2012 31, 3277–3286. LY294002 purchased from Selleck.

    PTEN transfection or inhibition of the PI3K-AKT and IGF-1R signaling pathways increases the trastuzumab sensitivity of NCI-N87/TR cells. After treating the cells with a PI3K inhibitor (LY294002), the expression of AKT and P-AKT proteins was assessed by Western blotting. Tubulin expression indicated equal loading. All gels run under the same experimental conditions and the experiments were repeated 3 times. The representative images were cropped and shown. Control: cells without any treatment.

    Sci Rep 2015 5, 11634. LY294002 purchased from Selleck.

  • SCC61 or Detroit 562 xenografted tumors respond to treatment by PI3K inhibitor, LY294002 alone, or in combination with gefitinib. % tumor growth is shown. By two-way ANOVA, the effect of treatment and time is considered significant;

    Mol Oncol 2013 7, 359-68. LY294002 purchased from Selleck.

    Inhibition of EGFR and PI3K/AKT pathway has additive effects in SCCHN cell lines with constitutively active PIK3CA mutations, while removing negative regulation of PI3K/AKT pathway increases resistance in sensitive SCCHN cell line. A, results from MTT assays on cells treated with PI3K inhibitor, LY294002, and gefitinib.

    Mol Oncol 2013 7, 359-68. LY294002 purchased from Selleck.

  • Immunofluorescence and flow cytometric analyses of the translocation of ABCG2 in MCF-7 FLV1000 cells before and after treatment with the PI3K inhibitor LY294002. Confocal microscopy of MCF-7 FLV1000 cells after a 16-h treatment with 2 uM or 4 uM of LY294002 was performed as described in Figure.

    Br J Pharmacol 2013 70(5), 1137-51. LY294002 purchased from Selleck.

    IGF1 increases apical fibronectin in late stage blastocysts. Representative confocal images of blastocysts stained for fibronectin (Green) and DAPI (Blue). Day 5 blastocysts were cultured in SS medium for 24 (A and B), 48 (C and D) or 72 h (E-H) in the absence (A, C and E) or presence (B, D and F) of 10 ng/ml IGF1 or in the presence of a PI3 Kinase inhibitor (5 uM LY294002 + 10 ng/ml IGF1) (G) or in the presence of 10 ng/ml IGF1, attached to a coverslip (H). Scale bars represent 20 mm. Red line indicates location of coverslip. Arrow indicates location of the inner cell mass (ICM). The following total number of blastocysts were analysed, from at least 3 experimental repeats in each treatment; 24 in the SS group (24 h), 21 in SS plus IGF1 (24 h), 26 in SS (48 h), 30 in SS plus IGF1 (48 h), 40 in SS (72 h), 59 in SS plus IGF1 (72 h), 13 in SS plus IGF1 + LY294002 (48 h) and 15 blastocysts were analysed that were attached to a coverslip (72 h).

    Hum Reprod 2015 30(2), 284-98. LY294002 purchased from Selleck.

  • Inhibition of PI3K, ERK and mTOR prevents the activation of S6K1 and S6 induced by suppression of PKD1 activity. A549 cells were incubated in the absence (-) or presence of either 5 uM Kb or 5 uM Kb and 20 uM LY294002 or 5 uM Kb and 10 uM BKM120 (as indicated) for 1 h prior to stimulation of cells with 50 nM PMA for 30 min and 1 h.

    Int J Biochem Cell Biol 2015 60, 34-42. LY294002 purchased from Selleck.

    Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823(5), 987-96. LY294002 purchased from Selleck.

  • Comparative effects of wortmannin and LY294002 on ADRP and β -casein synthesis. Con fluent HC11 cells were treated according to the standard procedure in the absence or presence of 4 ng/ml EGF either with or without 100 nM wortmannin or 50μM LY294002. Cellular proteins were analyzed by SDS-PAGE and immunoblot successively probed with anti-ADRP, anti-β-casein, anti-β -actin antibodies and their respective HRP-conjugated secondary antibodies. ECL signals were quantified by densitometry and normalized to β-actin. Each experimental condition was performed in triplicate. Percentages of inhibition for both inhibitor and hormonal treatments are indicated in the text.

    Biochim Biophys Acta 2012 1823(5), 987-96. LY294002 purchased from Selleck.

    We treated all of drugs in T47D which has a PI3KCA H1044R mutation with the concentration shown below for 1 hour and performed western blot analysis using antibodies to phospho-AKT(SERINE 472), and total AKT.

     

     

    2010 Saraswati Sukumar of Johns Hopkins University School of Medicine. LY294002 purchased from Selleck.

  • T47Dcells were pretreated with 100 ng/ml EGF for 20 min and then treated with the indicated concentrations of LY294002 for 24 hours.

     

     

    2010 Dr. Zhang of Tianjin Medical University. LY294002 purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.
Targets
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
0.5 μM 0.57 μM 0.97 μM
In vitro

LY294002 inactivates Akt/PKB, consequently inhibiting cell proliferation and inducing apoptosis. LY294002 demonstrates a remarkable growth-inhibitory and apoptosis-inducing effect in these colon cancer cell lines, with decreased expression of phosphorylated Akt (Ser473). [2]LY294002 induces marked nuclear pyknosis and diminished cytoplasmic volume in the tumor cells. Thus, LY294002 markedly inhibits ovarian cancer cell proliferation in vitro. LY294002 induces specific G1 arrest in cell growth, leading to almost complete inhibition of melanoma cell proliferation and partial inhibition of MG-63 (osteosarcoma cell line) proliferation. The effect of LY294002 on cell cycle progression may provide insights into a possible link between the PI3K activation pathway and cancer cell cycle regulation. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231 cells MoK4R4VtdCCrbo\hd4lwdiCjc4PhfS=> NWG2NHZ1OjRiaB?= NVfyXnU6UW6qaXLpeIlwdiCxZjDldIl1cGWuaXHsJIdzd3e2aDDmZYN1d3JvaX7keYNm\CClZXzsJI1q\3KjdHnvckBw\iCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJJBz\S2rbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBk\WyuIHnueoF{cW:wIHHzd4F6NCCLQ{WwQVAvOzhizszNMi=> NYC3d4NWOjJ6MESxNFg>
Sf21 cells MmTzSpVv[3Srb36gZZN{[Xl? MVXJcohq[mm2aX;uJI9nKG2xdYPlJJdqdGRidInw[UBRUTONYXzwbIEh\XiycnXzd4VlKGmwIGPmNlEh[2WubIOgZ48u\XiycnXzd4lv\yCQLYTldo1qdmGuIFjpd{11[WepZXSgbJVu[W5icEi1ZUB2e2mwZzDMMYFteGijLYDoc5NxcGG2aXT5cIlvd3OrdH;sJJN2[nO2cnH0[UBjgSCWTFOgZoF{\WRicHjvd5Bpd3JiaX3h[4lv\yxiSVO1NF0xNjVizszN M{j5OVIzPTJyNkOw
Sf21 cells MmPvSpVv[3Srb36gZZN{[Xl? NHTJclNKdmirYnn0bY9vKG:oIH3veZNmKHKnY3;tZolv[W62IGDJN2tidHCqYTDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiU3[yNUBk\WyuczygTWM2OD1yLkWg{txONg>? NXe5VmlFOTl5NEiyOlk>
Sf9 cells NUHKU3dITmy3b4Lld4NmdnRicH;sZZJqgmG2aX;uJIF{e2G7 NGLSbm9KdmirYnn0bY9vKG:oIHj1cYFvKFCLM1vhcJBp[SCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIJ6KG[udX;y[ZNk\W62IIDvcIFzcXqjdHnvckBie3OjeTygTWM2OD1yLkW1JO69VS5? M2PCRVIyOTJzNkOx
THP1 cells NXTrUI5bTnWwY4Tpc44h[XO|YYm= MVvJcohq[mm2aX;uJI9nKFOFRkGtbY5lfWOnZDDQT2IwSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDUTHAyKGOnbHzzMEBKSzVyPUGuNFEh|ryPLh?= NV7rWo9[OTZ5OEm3OFI>
human PC3 cells M3KyeGZ2dmO2aX;uJIF{e2G7 MWqzNEBucW5? NVHyOm1YUW6qaXLpeIlwdiCxZjDQTVNMKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IIPldolv\SB2N{OgZYZ1\XJiM{CgcYlveyCkeTDFUGlUSSxiSVO1NF0yNjQQvF2u NEHaeokzOzRzMECwOS=>
HeLa (human carcinoma) cells. NXTo[ZdiTnWwY4Tpc44h[XO|YYm= NIW3RpRKdiC4aYTyc{BqdmirYnn0bY9vKG:oIFTORU1l\XCnbnTlcpQheHKxdHXpckBscW6jc3WoSG5CNVCNKTDmdo9uKEinTHGgLIh2dWGwIHPhdoNqdm:vYTmgZ4VtdHNuIFnDOVA:OS52IN88UU4> Mn\BNVU3PTh6N{C=
THP1 cells Mn3uSpVv[3Srb36gZZN{[Xl? MlPxTY5pcWKrdHnvckBw\iCPQ2CxMYlv\HWlZXSgVGtDN0GtdDDwbI9{eGixconsZZRqd25iaX6gWGhROSClZXzsd{whUUN3ME2xMlY2KM7:TT6= MXWxOlc5QTd2Mh?=
HeLa cells NVnye4pnTnWwY4Tpc44h[XO|YYm= NVTJWmR3UW6qaXLpeIlwdiCxZjDtWG9TKHC{b4TlbY4hcXOxbHH0[YQh\nKxbTDI[WxiKGOnbHzzMEBKSzVyPUKuOUDPxE1w MoPwNVU3PTh6N{C=
human MCF7 cells NYjId3l{S3m2b4TvfIlkyqCjc4PhfS=> M1niSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMhcW5icILld4Vv[2Vib3[gNlAh|ryPIHPocI9zd3G3aX7lJIJ6KFOUQjDhd5NigSxiR1m1NF0zNjZ|IN88UU4> M3;Q[FE5PjlzOEm0
HeLa cells M2TmbWZ2dmO2aX;uJIF{e2G7 MoCzTY5pcWKrdHnvckBw\iCDWD23OVA{KGKrbnTpcochfG9icnXjc41jcW6jboSgVIxsOyCneIDy[ZN{\WRiaX6gTIVN[SClZXzsd{BjgSCZZYP0[ZJvKGKub4SsJGlEPT1|IN88UU4> NUHO[HE{OTdzM{WyOFg>
human MCF7 cells MULDfZRwfG:6aXRCpIF{e2G7 M{HkWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMhcW5icILld4Vv[2Vib3[gNVAhfU1iY3jsc5JweXWrbnWgZpkhW1KEIHHzd4F6NCCJSUWwQVMvODhizszNMi=> NGDkXlkyQDZ7MUi5OC=>
human MCF7 cells MlXZR5l1d3SxeHnjxsBie3OjeR?= MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m9N{4yPiEQvF2u MXixPFY6OTh7NB?=
human MDA-MB-231 cells MoToR5l1d3SxeHnjxsBie3OjeR?= M2\JXmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiMkCg{txOKGOqbH;yc5F2cW6nIHL5JHNTSiCjc4PhfUwhT0l;Mz6zNkDPxE1w MlqyNVg3QTF6OUS=
human MDA-MB-231 cells NWnVc29RS3m2b4TvfIlkyqCjc4PhfS=> NHXSTVVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEGwJJVOKGOqbH;yc5F2cW6nIHL5JHNTSiCjc4PhfUwhT0l3ME20MlM2KM7:TT6= NX3VTpZ2OTh4OUG4PVQ>
human MDA-MB-468 cells MmOxR5l1d3SxeHnjxsBie3OjeR?= NFXRc5lEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFY5KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEKwJJVOKGOqbH;yc5F2cW6nIHL5JHNTSiCjc4Phfg+9lCCLQ{WwQVQvPzZizszNMi=> MX[xPFY6OTh7NB?=
human HCT116 cells NHLSXJpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4\mN|Q5KGh? MnzwS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGNVOTF4IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJHBKO0ujbIDoZUBJOTB2N2KgcZV1[W62IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PS5|IN88US=> NVK1ZXNiOjJ{MUK3NlE>
human HCT116 cells NVLzT2w4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmHwOFghcA>? M{K5WWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVUvQCEQvF2u M{LTUVIzOjF{N{Kx
HeLa cells MXLCbY5lcW6pIHHm[olvcXS7IHHzd4F6 M3nicWJqdmSrbnegZYZncW6rdImg[o9zKFCLMz3rbY5ie2ViaYPvcIF1\WRiZoLvcUBJ\UyjIHPlcIx{NCCNaU22JO69VQ>? NHTYNGEyPTZ3OEi3NC=>
human HCT116 cells M2rpc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUe0PEBp NWW3OZZbT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUG2JINmdGy|IH;2[ZJmgHC{ZYPzbY5oKFCLM1vhcJBp[SCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVYvPyEQvF2u MoKzNlIzOTJ5MkG=
MDA-MB-231 cells MlnlR5l1d3SxeHnjxsBie3OjeR?= MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHL5JHNTSiCjc4PhfUwhT0l3ME22MlcyKM7:TT6= M17CcFE5PjlzOEm0
Sf9 cells NUHGOI17TnWwY4Tpc44h[XO|YYm= MmHmTY5pcWKrdHnvckBw\iCFS{Kg[ZhxemW|c3XkJIlvKFOoOTDj[YxteyxiSVO1NF03NjlizszNMi=> MWOxPFMzOTdzNh?=
human U87MG cells M{W4WWZ2dmO2aX;uJIF{e2G7 NVPLVFNnUW6qaXLpeIlwdiCxZjDHV2s{NWKndHGgbY4hcHWvYX6gWVg4VUdiY3XscJMh[nliRVzJV2EtKEmFNUC9PE4yKM7:TT6= Mo\pNVg{PDV4MEm=
human MDA-MB-468 cells M4DPXmN6fG:2b4jpZ:Kh[XO|YYm= MUHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy|IHnuJJBz\XOnbnPlJI9nKDFyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3OjeTygS2k2OD16LkKg{txONg>? MnS1NVg3QTF6OUS=
human A375 cells Mn73VJJwdGmoZYLheIlwdiCjc4PhfS=> NYjOXlNQPDZiaB?= Ml[0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDM{e1JINmdGy|IHHmeIVzKDR4IHjyd{whUUN3ME24MlQh|ryPLh?= MlHiNVcxPDl{NEi=
human A375 cells NX[2TZZZWHKxbHnm[ZJifGmxbjDhd5NigQ>? M1z5cGlvcGmkaYTpc44hd2Zic3XyeY0ucW6mdXPl[EBxem:uaX\ldoF1cW:wIH;mJIh2dWGwIFGzO|Uh[2WubIOsJGlEPTB;OD60JO69VS5? NYHFfWtmOTd4MEG3N|k>
human HL60 cells NFrSNJVEgXSxdH;4bYPDqGG|c3H5 NGPlSZU4OiCq NV\sTpNJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVkvQTRizszNMi=> NFHIOJgzOjR6MEi1NS=>
mouse Raw264 macrophage M4XwUmZ2dmO2aX;uJIF{e2G7 NGfOZlVKdmirYnn0bY9vKG:oIFO1ZU1u\WSrYYTl[EBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDpckBud3W|ZTDSZZczPjRibXHjdo9xcGGpZTygTWM2OD1zMDFOwG0v MVexOlc5QTd2Mh?=
Sf9 cells MYTGeY5kfGmxbjDhd5NigQ>? NIrNVFlKdmirYnn0bY9vKG:oIFjpd{11[WepZXSgZo93cW6nIGDJN2sh\XiycnXzd4VlKGmwIGPmPUBk\WyuczygTWM2OD1zMDFOwG0v NHHaWpIyODl7OEO1NS=>
human MDA-MB-468 cells NYPaR5V1S3m2b4TvfIlkyqCjc4PhfS=> M2G0OGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgZpkhW1KEIHHzd4F6NCCLQ{WwQVExNjRizszNMi=> M2fPelE5PjlzOEm0
human PC3 cell NIX3OIdRem:uaX\ldoF1cW:wIHHzd4F6 MmnQO|IhcA>? NIqxNYxKdmirYnn0bY9vKG:oIHj1cYFvKFCFMzDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IIPw[YN1em:yaH;0c41mfHKrYzDhcoFtgXOrczygTWM2OD1zMj6xJO69VS5? M4rBW|I{PDFyMEC1
human HL60 cells NWf5[oNnWHKxbHnm[ZJifGmxbjDhd5NigQ>? NWnsbIZUPzJiaB?= NIG5PIhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhZpNwemKjbnPlJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MUiuOFMh|ryPLh?= NXXBd41VOjV4OUO3PFc>
human BT474 cell MXjQdo9tcW[ncnH0bY9vKGG|c3H5 NGCxV|c4OiCq MnHiTY5pcWKrdHnvckBw\iCqdX3hckBDXDR5NDDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IIPw[YN1em:yaH;0c41mfHKrYzDhcoFtgXOrc,-8kEBKSzVyPUKwMlch|ryPLh?= MYmyN|QyODByNR?=
THP1 cells M{\OcWZ2dmO2aX;uJIF{e2G7 M2q2RWlvcGmkaYTpc44hd2ZiTVPQNU1qdmS3Y3XkJINp\W2xdHH4bZMhd2ZiVFjQNUBk\WyuczygTWM2OD1|NzFOwG0v NY\4O4JYOTZ5OEm3OFI>
human 184B5 cells MnflR5l1d3SxeHnjxsBie3OjeR?= M13KV2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJFE5PEJ3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1|OT6zO{DPxE1w NYm5TGtDOTh4OUG4PVQ>
human KB cells Mm\IR5l1d3SxeHnjxsBie3OjeR?= Mn;jO|IhcA>? MmjjR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2Ih[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD12ND63OkDPxE1w NXjsfJNCOjF7NEWyOVA>
mouse RAW264.7 cells MV7GeY5kfGmxbjDhd5NigQ>? MXSyOUDPxE1? NYm3RYRCOjBiaB?= NUnvUXF3UW6qaXLpeIlwdiCxZjDQTVNMN0GNVDDpckBud3W|ZTDSRXczPjRwNzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEySUz3pcoR2[2WmIHnOU3MheHKxdHXpckBmgHC{ZYPzbY9vKGG2IEK1JO69VSCjZoTldkAzOCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NF\PeZkzPDJ7OU[xOi=>
human A2780 cells NX73cIlESXCxcITvd4l{KGG|c3H5 Ml\CNkDPxE1? MlPjNVIhcA>? MknlTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDjbZNxdGG2aX6tdoV{cXO2YX70JIh2dWGwIFGyO|gxKGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIIDoc5NxcG:{eXzheIVlKEGtdDDs[ZZmdCCjdDCyJJVOKGGodHXyJFEzKGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{Ng>? MUOxO|Y5PDBzOB?=
human SW480 cells MUDGeY5kfGmxbjDhd5NigQ>? M1\PU|IxKM7:TR?= Ml25NlQhcA>? M{TJbGRm[3KnYYPlJIlvKHO3co\peolvKGW6cILld5Nqd25iaX6gbJVu[W5iU2e0PFAh[2WubIOgZZQhOjBidV2gZYZ1\XJiMkSgbJJ{KGK7IHntcZVvd2Kub4SgZY5idHm|aYO= MlrmNVc1PzJ7NkK=
mouse mast cells MV\GeY5kfGmxbjDhd5NigQ>? MYmyNEDPxE1? NI\qU4NKdmirYnn0bY9vKG:oIGPDSk1qdmS3Y3XkJHBMSi:Da4SgdIhwe3Cqb4L5cIF1cW:wIHnuJI1wfXOnIH3hd5Qh[2WubIOgZZQhOjBizszN NY\qcnpOOTZ5OEm3OFI>
human BJ cells NYfpU5ZkTnWwY4Tpc44h[XO|YYm= NUixTFZ{OjVizszN NVLnVlQyOiCq M1LEe2lvcGmkaYTpc44hd2ZiUFmzT{B{cWewYXzpcochcW5iUFTHSk1{fGmvdXzheIVlKHOncoXtJJN1[XK4ZXSgbJVu[W5iQlqgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCybHHzcYllKEWJRmCvVGgh\G:vYXnuJI9nKEGtdDDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDQTE1GT0[SIILl[Il{fHKrYoX0bY9vKHSxIIDsZZNu[SCvZX3idoFv\SCjdDCyOUB2VSC2cnXheIVlKDJiaILzJIJm\m:{ZTDQSGdHKGOqYXzs[Y5o\SCkeTDjc45nd2OjbDDtbYNzd3Olb4D5 NELKeZoyPjd4N{C4OS=>
human IGROV1 cells NV7reGtOTnWwY4Tpc44h[XO|YYm= NWD1PGY2OjRxNEigbC=> NGK1SXpKdmirYnn0bY9vKG:oIGDJN2swSWu2IHnuJIh2dWGwIFnHVm9XOSClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDwbI9{eGixconsZZRm\CCDS2SgcIV3\WxiYYSgNUB1dyB3IITpcYV{KEmFNUCgZYZ1\XJiMkSgeI8hPDhiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NYfxR3FFOjF{MU[xOVE>
human IGROV1 cells M4DCb2Z2dmO2aX;uJIF{e2G7 M4fmOVI1NzR6IHi= MW\Jcohq[mm2aX;uJI9nKFCLM1uvRYt1KGmwIHj1cYFvKEmJUl;WNUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCleXPsbY4hTDFibHX2[Ywh[XRiMTD0c{A2KHSrbXXzJGlEPTBiYX\0[ZIhOjRidH:gOFghcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NUHSNVNyOjF{MU[xOVE>
rat RBL2H3 cells MnXZSpVv[3Srb36gZZN{[Xl? NXnIUnYzUW6qaXLpeIlwdiCxZjDBNlMyQDdvaX7keYNm\CCmZXfyZY52dGG2aX;uJIlvKHKjdDDSRmwzUDNiY3XscJM> NIjGbmMyQDN{OEexOi=>
human BJ cells MmPHSpVv[3Srb36gZZN{[Xl? M2\SdVI2KM7:TR?= NHywVZMzKGh? Mn3vRYN1cX[jdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHH0JHRpejNyODDpckBRTEeILYP0bY12dGG2ZXSgd4VzfW1ic4ThdpZm\CCqdX3hckBDUiClZXzsd{BifCB{NTD1UUB1emWjdHXkJFIhcHK|IHLl[o9z\SCSRFfGJINp[WyuZX7n[UBjgSCrbX31co9jdG:2dHnu[y=> Mk\1NVY4PjdyOEW=
human HCT116 cells NEXCS4xHfW6ldHnvckBie3OjeR?= NXH0RWR4OTBizszN MX:xNEBucW5? M3W5cmlvcGmkaYTpc44hd2ZiUFmzT4FteGijIHnuJIh2dWGwIFjDWFEyPiClZXzsd{B2e2mwZzDbN|JRZUGWUDDheEAyOCC3TTDh[pRmeiBzMDDtbY5{ NYj2cWR4OjJ{MUK3NlE>
human HCT116 cells MlKxSpVv[3Srb36gZZN{[Xl? NF;me4YyOCEQvF2= NH;qbXQyOCCvaX6= NYLsb5VUUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgTFExPDeUIH31eIFvfCCrbjDoeY1idiCKQ2SxNVYh[2WubIOgeZNqdmdiW{OyVH1CXFBiYYSgNVAhfU1iYX\0[ZIhOTBibXnudy=> MVuyNlIyOjd{MR?=
human HCT116 cells NEPhfpNHfW6ldHnvckBie3OjeR?= MX6xNEDPxE1? NEHFcoFKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDpckBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBCc3RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBifCBzMDD1UUBjgSCrbX31co9jdG:2IHHuZYx6e2m| MnvPNlIzOTJ5MkG=
human HCT116 cells NXznOHZqTnWwY4Tpc44h[XO|YYm= NXiyUWZYOTBizszN MULJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCKMUC0O3IhdXW2YX70JIlvKGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGtdDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGG2IEGwJJVOKGK7IHntcZVvd2Kub4SgZY5idHm|aYO= MVGyNlIyOjd{MR?=
human PC3 cells NHnndVZHfW6ldHnvckBie3OjeR?= MoC5OVAh|ryP NHfwXZk5KGh? MVnJcoR2[3Srb36gc4YheDJzIIDyc5RmcW5iZYjwdoV{e2mxbjDpckBpfW2jbjDQR|Mh[2WubIOgZZQhPTBidV2gbY5kfWKjdHXkJIZweiB6IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5oKHKnbHH0bZZmKHSxIIXueJJm[XSnZDDjc451em:u NWW2SGVYOjJ7OUi0O|I>
human LNCAP cells MnPSSpVv[3Srb36gZZN{[Xl? MlnkNE4yNTNyIN88US=> NWLKRZBiOzBibXnu NWO0d4FUUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGxPS0GSIHPlcIx{KGG2IECuNUB1dyB|MDD1UUBi\nSncjCzNEBucW6|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? Mk\YNlI5OzJ|MU[=
human LNCAP cells MkfDSpVv[3Srb36gZZN{[Xl? NWTScooxOC5zLUOwJO69VQ>? NVPWXJZsOjRiaB?= M33RZWRwf26{ZXf1cIF1cW:wIH;mJJN2en[rdnnuJIV5eHKnc4Ppc44hcW5iaIXtZY4hVE6FQWCgZ4VtdHNiYYSgNE4yKHSxIEOwJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? M{TiVVIzQDN{M{G2
HUVEC MkPoSpVv[3Srb36gZZN{[Xl? MVixNE0zPSEQvF2= Mlq1NVYhcA>? M3\KZWlvcGmkaYTpc44hd2ZiVF7GZYxxcGFvc4TpcZVt[XSnZDDJR2FONTFibWLORUBmgHC{ZYPzbY9vKGmwIFjVWmVEKGG2IEGwJJRwKDJ3IIXNJJBz\XS{ZXH0[YQh\m:{IEG2JIhzeyCkZX\vdoUhXE6IYXzwbIEh[2ijbHzlcodmKG2nYYP1doVlKGGodHXyJFYhcHK|IHL5JHJVNVCFUjDhcoFtgXOrcx?= NY\zN4ZQOjJyMk[0NVA>
HUVEC NWHqVYF{TnWwY4Tpc44h[XO|YYm= M{DyTFExNTJ3IN88US=> MV:zNEBucW5? NInpUHRKdmirYnn0bY9vKG:oIGTOSoFteGijLYP0bY12dGG2ZXSgbJVu[W5iSVPBUU0yKHC{b33veIVzKGGldHn2bZR6KGW6cILld5Nm\CCrbjDIWXZGSyCjc4Pld5Nm\CCjczDi[ZRiNWejbHHjeI9{cWSjc3WgZYN1cX[rdImgZZQhOTBidH:gNlUhfU1icILleJJm[XSnZDDmc5IhOzBibXnud{Bj\W[xcnWgWG5H[WyyaHGgZ4hidGynbnflJI1m[XO3cnXkJIFnfGW{IEWgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=> M1jwZlIzODJ4NEGw
human H1299 cells Ml:zSpVv[3Srb36gZZN{[Xl? NEjpUlAxNjFvM{Cg{txO MXuyOEBp M2rBWGRwf25icnXneYxifGmxbjDv[kBkUUGSMjDlfJBz\XO|aX;uJIlvKGi3bXHuJGgyOjl7IHPlcIx{KGG2IECuNUB1dyB|MDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ MkTMNlI3OjJyNkm=
human H1299 cells MoXwSpVv[3Srb36gZZN{[Xl? MlLoNE4yNTNyIN88US=> M1HYSVI1KGh? MWrEc5dvKHKnZ4XsZZRqd25ib3[gZ2lCWDJiZYjwdoV{e2mxbjDpckBpfW2jbjDINVI6QSClZXzsd{BifCByLkGgeI8hOzBidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpd{BqdiCycnXz[Y5k\SCxZjCxNFAhfWdxbXygWHJCUUxiYX7kJHBKO0tiaX7obYJqfG:{IFzZNlk1ODB{ MXmyNlYzOjB4OR?=
human H1299 cells Mm[3SpVv[3Srb36gZZN{[Xl? MViwMlEuOzBizszN NXzObJV4OjRiaB?= M1\GbWlv\HWldHnvckBw\iCGUkWg[ZhxemW|c3nvckBqdiCqdX3hckBJOTJ7OTDj[YxteyCjdDCwMlEhfG9iM{CgeW0h[W[2ZYKgNlQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? MkfkNlI3OjJyNkm=
human H1299 cells Ml3GSpVv[3Srb36gZZN{[Xl? M{nKZ|AvOS1|MDFOwG0> NIXsT4czPCCq M3[5V2lv\HWldHnvckBw\iCMTlutcYVlcWG2ZXSgR2hQWCCneIDy[ZN{cW:wIHnuJIh2dWGwIFixNlk6KGOnbHzzJIF1KDBwMTD0c{A{OCC3TTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz M{HyV|IzPjJ{ME[5
HEK293 cells M{HtNWZ2dmO2aX;uJIF{e2G7 M{T1e|EvPSCq NInoOpZFcXOybHHj[Y1mdnRib3[gX|NJZUyVRDDmdo9uKGi3bXHuJFVJXDZicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjZoTldkAyNjViaILzJIJ6KGyrcYXp[EB{[2mwdHnscIF1cW:wIHPveY51cW6p Ml;CNlI2OzdzNUO=
human U251HRE cells MWXGeY5kfGmxbjDhd5NigQ>? M{jFbmlvcGmkaYTpc44hd2ZiaInwc5hq[S2rbnT1Z4VlKEiLRkGgZYN1cX[jdHnvckBqdiCqdX3hckBWOjVzSGLFJINmdGy|IHL5JINmdGxiYnHz[YQhemWyb4L0[ZIh\2WwZTDhd5NigQ>? NFTlR20yQDVyMU[wNS=>
human HCT116 cells MnLQSpVv[3Srb36gZZN{[Xl? MkfUNVAh|ryP MmDHTY5pcWKrdHnvckBw\iCDa4Sg[ZhxemW|c3nvckBqdiCqdX3hckBJS1RzMU[gZ4VtdHNiYYSgNVAhfU1iYomgbY1ufW6xYnzveEBidmGueYPpdy=> NEPvN|AzOjJzMkeyNS=>
Sf9 cells MkTm[ox2d3Knc3PlcpQheG:uYYLpfoF1cW:wIHHzd4F6 M{DjSGlvcGmkaYTpc44hd2ZiaIXtZY4hWEl|S3fhcY1iKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZpkh\my3b4Lld4NmdnRicH;sZZJqgmG2aX;uJIF{e2G7 M3fpT|IyOTJzNkOx
human HCT116 cells M1T1WnBzd2yrZnXyZZRqd25iYYPzZZk> MWS3NkBp MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD13MT64NkDPxE1w M1XjdlI2Pjl|N{i3
human HCT116 cells M2T5[mN6fG:2b4jpZ:Kh[XO|YYm= NVyzWotUPzJiaB?= NEn0XmNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF02Pi5yMTFOwG0v MVSyNVk1PTJ3MB?=
human PC3 cells NXnBOnJNS3m2b4TvfIlkyqCjc4PhfS=> MoTOO|IhcA>? Mmm5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NkGuN|Uh|ryPLh?= NULzTYZrOjJ2OEC4OVE>
human HuH7 cells NIPVXGdRem:uaX\ldoF1cW:wIHHzd4F6 M2r3blczKGh? NX\XV4cySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIeWg4KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZYJ{d3KkYX7j[UBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPU[3MlE5KM7:TT6= MX2yOVY6Ozd6Nx?=
human A549 cells M{G0eXBzd2yrZnXyZZRqd25iYYPzZZk> MWm3NkBp MYTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCjYoPvdoJidmOnIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:QDJwM{Kg{txONg>? MkHuNlU3QTN5OEe=
human A549 cells MXXDfZRwfG:6aXRCpIF{e2G7 M2PjV|czKGh? NHTVenhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZk> M3q0Z|IzPDhyOEWx
human PC3 cells NIPz[3VRem:uaX\ldoF1cW:wIHHzd4F6 NYrFT2FEOjVizszN NXnLUVZYOTJyIHi= MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyCjdDCyOUB2VSCjZoTldkAyOjBiaILzJIJ6KE2WVDDhd5NigSC{ZXzheIl3\SC2bzDEUXNQ MX2xOlY5ODF3OR?=
human H460 cells NGXETYVHfW6ldHnvckBie3OjeR?= MVSzNEDPxE1? NVjZRZJtUW6qaXLpeIlwdiCxZjDQTVNMKGmwIHj1cYFvKEh2NkCgZ4VtdHNiYYPz[ZN{\WRiYYOgRYt1KHCqb4PwbI9zgWyjdHnvckBifCCVZYKgOFc{KHWyIITvJFMxKHWP NHPGNJkyQDVyMU[wNS=>
human IGROV1 cells Mn3jSpVv[3Srb36gZZN{[Xl? MnjSNlQhcA>? M1TsdmNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGlIWk:YMTDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{GgdIhie2ViYYSgNUBnd2ymIFnDOVAh[W[2ZYKgNlQhcHK|IHL5JIZtd3diY4n0c41mfHK7 MV6yNVIyPjF3MR?=
human IGROV1 cells MUnGeY5kfGmxbjDhd5NigQ>? MWmyOEBp M{\GTGNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGlIWk:YMTDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{GgdIhie2ViYYSgOUBnd2ymIFnDOVAh[W[2ZYKgNlQhcHK|IHL5JIZtd3diY4n0c41mfHK7 NVr5cGFGOjF{MU[xOVE>
human H4 cells MkO1SpVv[3Srb36gZZN{[Xl? NEO3S5gzKGh? NXfTNnZbTGWlcnXhd4UhcW5iRmnWSU1TTlBtII\ld4lkdGViaX70[Y5{cXS7IIDldkBk\WyuIHnuJIh2dWGwIFi0JINmdGy|IHHmeIVzKDJiaILzJJJmdGG2aY\lJJRwKGOxboTyc4w> MXGxPFAzPDV6NB?=
human MGC803 cells MX\GeY5kfGmxbjDhd5NigQ>? MYqyOUDPxE1? M4TtTlQ5KGh? Mo\DR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gUWdEQDB|IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBifCCJMj;NJJBp[XOnIHH0JFI2KHWPIHHmeIVzKDR6IHjyd{B2e2mwZzDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHHmeIVzKDR6IHjyd{BjgSCobH;3JIN6fG:vZYTldkBz\WyjdHn2[UB1dyClb370do9t MkftNlQyOTl6Nkm=

... Click to View More Cell Line Experimental Data

In vivo LY294002 also results in suppression of tumor growth and induction of apoptosis, especially in the LoVo tumors, and therefore shows remarkable effectiveness in the mouse peritonitis carcinomatosa model. [2] LY294002 significantly inhibits growth and ascites formation of ovarian carcinoma. [3]

Protocol

Kinase Assay:[4]
+ Expand

kinase assays:

PI3K inhibition by LY294002 is determined in a radiometric assay using purified, recombinant enzymes with 1 μM ATP. The kinase reaction is carried out for 1 hour at room temperature (24oC) and is terminated by addition of PBS. IC50 values are subsequently determined using a sigmoidal dose–response curve fit (variable slope). CK2 and GSK3β (glycogen synthase kinase 3β) inhibition is established by kinase selectivity screening. LY294002 is tested against the Upstate panel of kinases in 10 μM ATP.
Cell Research:[2]
+ Expand
  • Cell lines: Colon cancer cell lines DLD-1, LoVo, HCT15, and Colo205
  • Concentrations: 0–50 μM
  • Incubation Time: 0–48 hours
  • Method: 1.0×105 cells (100 μL volume/well) are inoculated into 96-well microtiter plates. LY294002 is added to triplicate wells and cultured at 37oC for 0–48 hours. After treatment, 10 μL of Premix WST-1 are added to each microculture well, and the plates are incubated for 60 minutes at 37oC, after which absorbance at 450 nm is measured with a microplate reader.
    (Only for Reference)
Animal Research:[3]
+ Expand
  • Animal Models: Two groups of athymic nude mice (5–7 weeks) are inoculated i.p. with OVCAR-3 cells
  • Formulation: Dissolved in DMSO plus 0.25 ml of PBS
  • Dosages: 0–100 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 36 mg/mL (117.13 mM)
Ethanol 21 mg/mL (68.32 mM)
Water <1 mg/mL
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 307.34
Formula

C19H17NO3

CAS No. 154447-36-6
Storage powder
in solvent
Synonyms SF 1101, NSC 697286

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy LY294002 | LY294002 supplier | purchase LY294002 | LY294002 cost | LY294002 manufacturer | order LY294002 | LY294002 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID